Tricog Health is a technology company.
Tricog Health has raised $11.0M across 1 funding round.
Tricog Health has raised $11.0M in total across 1 funding round.
Tricog Health has raised $11.0M in total across 1 funding round.
Tricog Health's investors include Blume Ventures.
Tricog Health is a health AI company founded in 2014 that develops diagnostic platforms like InstaECG, InstaEcho, and Keebo to enable real-time detection of over 140 cardiac conditions using AI, proprietary hardware, and medical expert review.[1][3][6] It serves clinics, hospitals, diagnostics centers, public health facilities, and home health services across 12-16 countries in Asia, Africa, and Southeast Asia, addressing gaps in timely access (42%) and quality of care (58%) for cardiovascular diseases (CVD) by digitizing ECG/EKG workflows and accelerating diagnosis within minutes.[1][2][4][6] The company has screened over 31 million patients, identified ~1 million critical cases, and claims to have saved 900K+ lives, with strong growth via partnerships like OMRON and AstraZeneca targeting 100 million people by 2030.[1][3][6]
Tricog Health was founded in 2014 in Bengaluru, India, by interventional cardiologist Dr. Charit Bhograj (CEO), along with Zainul Charbiwala and Udayan Dasgupta, driven by the need for instant, accurate cardiac diagnosis to combat high heart attack mortality rates—aiming to shift from an 80% fatality chance to 80% survival.[5][6][7] Bhograj's clinical background highlighted infrastructure gaps in primary care, leading to proprietary AI models that digitize and analyze ECGs/Echos in real-time, initially focusing on India before expanding globally.[3][6] Early traction came from deploying in 5,000+ locations (98% previously without ECG access), screening 10M+ patients by 2023, and partnerships that scaled to 31M+ diagnoses, including collaborations with AstraZeneca for Africa.[3][4][6]
Tricog rides the AI-driven preventive cardiology wave, leveraging foundation models for CVD—a leading global killer—amid rising demand in low-resource regions where specialist shortages delay diagnosis.[1][2][6] Timing aligns with post-pandemic telehealth adoption and investments in digital health ecosystems, amplified by partnerships with device giants (OMRON) and pharma (AstraZeneca) to bridge primary-to-tertiary gaps and generate real-world evidence.[3][6] Market forces like aging populations, CVD prevalence in emerging markets (India, Africa, SE Asia), and falling AI compute costs favor scalable, subscription-based diagnostics; Tricog influences the ecosystem by standardizing care pathways, enabling last-mile interventions, and proving AI's role in reducing mortalities (e.g., door-to-balloon time).[1][4][6]
Tricog is poised for hypergrowth toward its 100M-patient goal by 2030, expanding Keebo platform rollouts with OMRON for home-hospital integration and AstraZeneca for Africa/Asia, while advancing multimodal AI for predictive CVD management.[3][6] Trends like edge AI, wearable integration, and regulatory nods for AI diagnostics will accelerate adoption, potentially evolving Tricog into a global CVD platform leader. This builds on its core strength—timely AI-expert diagnosis saving lives at scale—positioning it to transform cardiac care from reactive to predictive in underserved markets.[1][6]
Tricog Health has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series B in March 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2020 | $11.0M Series B | Blume Ventures |